CD3E and neoplasm: Simultaneous binding of NILK-2301 to CEACAM5-positive tumor cells and CD3ε-expressing T-cells leads to T-cell activation, proliferation, and secretion of cytokines and cytotoxic enzymes, ultimately leading to tumor cell killing.